Gapping up
In reaction to strong earnings/guidance:
- CMD +1.8%, RAD +1.6%
Other news:
- CBMG +20.6% (enters licensing and collaboration agreement with Novartis (NVS) to manufacture and supply the CAR-T cell therapy Kymriah in China NVS will acquire $40 mln in stock at $27.43/share)
- CCJ +16% (Tax Court of Canada rules in favour of Cameco)
- PTGX +10.4% (FDA has granted Fast Track designation to therapeutic candidate PTG-300 for the treatment of chronic anemia due to ineffective erythropoiesis in patients with beta-thalassemia)
- EQC +3.1% (declares special cash distribution of $2.50/share)
- TLRY +2.6% (ongoing volatility)
- ALNY +1.9% (announces 'positive' topline results from the interim analysis of the ENVISION Phase 3 Study of givosiran for the treatment of acute hepatic porphyria)
- WCG +1.8% (to acquire Aetna's (AET) entire standalone Medicare Part D prescription drug plan business)
- AZO +1.5% (authorized the repurchase of an additional $1.250 bln of common stock)
- ATTO +1.3% (Atento signs strategic agreement with Deutsche Telekom [DTEGY] unit T-Systems on the provision of data center services in Brazil)
- AMZN +0.8% (Amazon is opening an 'Amazon 4-star' store in Manhattan's SoHo neighborhood tomorrow, featuring items rated four stars or higher, top sellers, or new and trending on Amazon.com)
Analyst comments:
- HAIR +13.6% (initiated with Outperform at William Blair)
- CYBR +4.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- TSG +4.4% (initiated with a Buy at Goldman)
- AYR +2.3% (upgraded to Outperform from Market Perform at Cowen)
- STNG +2.1% (initiated with Buy ratings at BTIG Research)
- KMX +1.8% (upgraded to Outperform from Neutral at Robert Baird)
- AAPL +1.5% (initiated with a Overweight at JP Morgan)
- PYPL +1% (initiated with Outperform at BMO Capital Mkts)
- MA +0.9% (initiated with Outperform at BMO Capital Mkts)
![]()